A Phase 2 interventional study of Cisplatin and Standard Fractionation Radiotherapy in Head and Neck Cancer and Squamous Cell Carcinoma, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing panitumumab in Head and Neck Neoplasms — 3 open to participants now, 3 under way, none of them phase 3. Panitumumab · Head and Neck Neoplasms.
Among the 14 studies testing panitumumab in Head and Neck Neoplasms, this one is the 2nd largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 2, and was the 2nd registered.
2,716 studies on the registry are indexed under Head and Neck Neoplasms; 598 are open to participants now.
Browse Head and Neck Neoplasms studies →3 of the 14 studies testing panitumumab in Head and Neck Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 46 across 2,034 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 43 across the 14 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 8 studies filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing panitumumab in Head and Neck Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed. The study is investigating if the addition of a targeted therapy (panitumumab) can improve the efficacy of chemoradiation without adding unmanageable toxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m\^2 and panitumumab 9 mg/kg on Days 1, 22 and 43.
Drug: Cisplatin · Radiation: Standard Fractionation Radiotherapy · Drug: Panitumumab
Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m\^2 on Days 1, 22, and 43.
Drug: Cisplatin · Radiation: Standard Fractionation Radiotherapy
Administered intravenously (IV; in a vein)
70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
Administered intravenously
Also known as: Vectibix®
Local Regional Control Rate at 2 Years
In this study participants were considered to be in local regional control (LRC) if there was no evidence of active disease in the previously affected/irradiated head-and-neck area. LRC could be achieved at any time following completion of treatment unless disease progression in the local-regional area occurred or the participant received subsequent anti-tumor therapy. Local regional control rate is defined as the Kaplan-Meier (KM) estimate of the proportion of participants with local regional control.
Time frame: 2 years
Local Regional Control Rate at 6 Months and 12 Months
Participants were considered to be in local regional control (LRC) if there was no evidence of active disease in the previously affected/irradiated head-and-neck area. LRC could be achieved at any time following completion of treatment unless disease progression in the local-regional area occurred or the participant received subsequent anti-tumor therapy. Local regional control rate is defined as the Kaplan-Meier (KM) estimate of the proportion of participants with local regional control.
Time frame: 6 months and 12 months
Duration of Local-regional Control
Duration of local regional control is calculated from the first day of any study treatment (radiotherapy, chemotherapy, or panitumumab) administration to the date of first local-regional failure or to death due to any cause (whichever occurs first). Local-regional failure includes persistent disease and local-regional recurrence of disease. Participants who did not meet the criteria for LRC recurrence after achieving a response by the analysis data cutoff date were censored at their last evaluable disease assessment date. Participants who never achieved LRC were considered to have a duration of 0.
Time frame: From first dose up to 37 months
Progression-Free Survival
Progression-free survival time is defined as time from the first day of any study treatment to date of first progresive disease using a modified version of the World Health Organization (WHO) criteria or death. Progressive Disease is defined as at least a 25% increase in the size of index lesions or unequivocal progression of existing non-index lesions or the presence of one or more new lesions. Participants not meeting these criteria by the cutoff date were censored at their last evaluable disease assessment date.
Time frame: From first dose date to 37 months
Overall Survival
Survival time is defined as time from the first day of any study treatment to date of death. Participants who had not died by the cutoff date were censored at their last contact date.
Time frame: From first dose date up to 37 months
Percentage of Participants With an Objective Response at 6 Months
Objective response by 6 months is defined as a complete response or partial response based on central review of scans using a a modification of the WHO criteria during the first 6 months. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the size of index lesions with no progression in non-index lesions, or the disappearance of all index lesions and persistence of 1 or more non-index lesions not qualifying for either CR or progressive disease and no new lesions.
Time frame: 6 months
Percentage of Participants With a Complete Response at 6 Months
Response assessment based on central review of scans using a a modification of the WHO criteria, during the first 6 months. Complete Response is defined as the disappearance of all index and non-index lesions and no new lesions.
Time frame: 6 months
153 patients were enrolled with 89 patients on panitumumab plus chemoradiation arm, and 64 patients on chemoradiotherapy alone arm.
| Milestone | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone |
|---|---|---|
| Started | 89 | 64 |
| Received treatment | 87 | 63 |
| Completed | 46 | 40 |
| Not completed | 43 | 24 |
| Withdrew: Death | 32 | 15 |
| Withdrew: Withdrawal by subject | 5 | 7 |
| Withdrew: Administrative decision | 2 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Other | 1 | 2 |
In this study participants were considered to be in local regional control (LRC) if there was no evidence of active disease in the previously affected/irradiated head-and-neck area. LRC could be achieved at any time following completion of treatment unless disease progression in the local-regional area occurred or the participant received subsequent anti-tumor therapy. Local regional control rate is defined as the Kaplan-Meier (KM) estimate of the proportion of participants with local regional control.
| proportion of paticipants | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone |
|---|---|---|
| Local Regional Control Rate at 2 Years | 0.61 (0.50 to 0.71) | 0.68 (0.54 to 0.78) |
Participants were considered to be in local regional control (LRC) if there was no evidence of active disease in the previously affected/irradiated head-and-neck area. LRC could be achieved at any time following completion of treatment unless disease progression in the local-regional area occurred or the participant received subsequent anti-tumor therapy. Local regional control rate is defined as the Kaplan-Meier (KM) estimate of the proportion of participants with local regional control.
| proportion of paticipants | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone |
|---|---|---|
| 6 months | 0.70 (0.59 to 0.79) | 0.73 (0.60 to 0.83) |
| 12 months | 0.66 (0.55 to 0.75) | 0.70 (0.56 to 0.80) |
Duration of local regional control is calculated from the first day of any study treatment (radiotherapy, chemotherapy, or panitumumab) administration to the date of first local-regional failure or to death due to any cause (whichever occurs first). Local-regional failure includes persistent disease and local-regional recurrence of disease. Participants who did not meet the criteria for LRC recurrence after achieving a response by the analysis data cutoff date were censored at their last evaluable disease assessment date. Participants who never achieved LRC were considered to have a duration of 0.
| months | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone |
|---|---|---|
| Duration of Local-regional Control | 33.7 (28.8 to NA) | NA (NA to NA) |
Progression-free survival time is defined as time from the first day of any study treatment to date of first progresive disease using a modified version of the World Health Organization (WHO) criteria or death. Progressive Disease is defined as at least a 25% increase in the size of index lesions or unequivocal progression of existing non-index lesions or the presence of one or more new lesions. Participants not meeting these criteria by the cutoff date were censored at their last evaluable disease assessment date.
| months | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone |
|---|---|---|
| Progression-Free Survival | NA (24.3 to NA) | NA (25.6 to NA) |
Survival time is defined as time from the first day of any study treatment to date of death. Participants who had not died by the cutoff date were censored at their last contact date.
| months | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone |
|---|---|---|
| Overall Survival | 33.7 (32.2 to NA) | NA (34.6 to NA) |
Objective response by 6 months is defined as a complete response or partial response based on central review of scans using a a modification of the WHO criteria during the first 6 months. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the size of index lesions with no progression in non-index lesions, or the disappearance of all index lesions and persistence of 1 or more non-index lesions not qualifying for either CR or progressive disease and no new lesions.
| percentage of participants | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone |
|---|---|---|
| Percentage of Participants With an Objective Response at 6 Months | 71.26 (60.57 to 80.46) | 82.26 (70.47 to 90.80) |
Response assessment based on central review of scans using a a modification of the WHO criteria, during the first 6 months. Complete Response is defined as the disappearance of all index and non-index lesions and no new lesions.
| percentage of participants | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone |
|---|---|---|
| Percentage of Participants With a Complete Response at 6 Months | 20.69 (12.75 to 30.71) | 19.35 (10.42 to 31.37) |
Collected over The median reporting period was around 82 days in the Panitumumab Plus Chemoradiation arm, and around 80 days in the Chemoradiotherapy Alone arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab Plus Chemoradiation | — | 37/87 (42.5%) | 87/87 (100%) |
| Chemotherapy Plus Radiotherapy | — | 20/63 (31.7%) | 63/63 (100%) |
| Event | Panitumumab Plus Chemoradiation | Chemotherapy Plus Radiotherapy |
|---|---|---|
| DysphagiaGastrointestinal disorders | 6/87 | 4/63 |
| NauseaGastrointestinal disorders | 6/87 | 4/63 |
| Mucosal inflammationGeneral disorders | 6/87 | 1/63 |
| VomitingGastrointestinal disorders | 5/87 | 4/63 |
| PyrexiaGeneral disorders | 5/87 | 1/63 |
| Radiation skin injuryInjury, poisoning and procedural complications | 5/87 | 0/63 |
| DehydrationMetabolism and nutrition disorders | 5/87 | 2/63 |
| Renal failureRenal and urinary disorders | 0/87 | 3/63 |
| General physical health deteriorationGeneral disorders | 3/87 | 1/63 |
| PneumoniaInfections and infestations | 3/87 | 2/63 |
| Event | Panitumumab Plus Chemoradiation | Chemotherapy Plus Radiotherapy |
|---|---|---|
| Radiation skin injuryInjury, poisoning and procedural complications | 58/87 | 52/63 |
| Mucosal inflammationGeneral disorders | 71/87 | 45/63 |
| DysphagiaGastrointestinal disorders | 55/87 | 40/63 |
| NauseaGastrointestinal disorders | 45/87 | 36/63 |
| Dry mouthGastrointestinal disorders | 41/87 | 33/63 |
| RashSkin and subcutaneous tissue disorders | 40/87 | 1/63 |
| Weight decreasedInvestigations | 37/87 | 28/63 |
| DysgeusiaNervous system disorders | 21/87 | 27/63 |
| ConstipationGastrointestinal disorders | 34/87 | 21/63 |
| VomitingGastrointestinal disorders | 29/87 | 21/63 |
| Age, Continuous(Years) | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| Mean | 58.0 ± 8.4 | 56.6 ± 8.8 | 57.4 ± 8.5 |
| Sex: Female, Male(Participants) | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| Female | 13 | 7 | 20 |
| Male | 76 | 57 | 133 |
| Race/Ethnicity, Customized(Participants) | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| White or Caucasian | 82 | 55 | 137 |
| Black or African American | 0 | 1 | 1 |
| Hispanic or Latino | 3 | 0 | 3 |
| Asian | 4 | 8 | 12 |
| Radiotherapy delivery modality(Participants) | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| IMRT | 52 | 42 | 94 |
| 3D-CRT | 35 | 21 | 56 |
| Missing | 2 | 1 | 3 |
| Primary tumor site(Participants) | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| Oropharynx/Larynx | 68 | 41 | 109 |
| Oral Cavity/Hypopharynx | 21 | 23 | 44 |
| Nodal status(Participants) | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| N0 | 12 | 9 | 21 |
| N+ | 77 | 55 | 132 |
| Tumor stage(Participants) | Panitumumab Plus Chemoradiation | Chemoradiotherapy Alone | Total |
|---|---|---|---|
| T1-3 | 64 | 45 | 109 |
| T4 | 25 | 19 | 44 |
No study locations are listed for this record.
Ran from Oct 2007 to primary completion in Mar 2011, 41 months.
Results were first posted in Aug 2014, 3 years 4 months after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 41 months is above that.
Counting every sponsor, half of 260 studies reached it within 51 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab